Cogent Biosciences Shares Fall After Public Offering News

Dow Jones

Jul 09, 2025

By Stephen Nakrosis

Shares of Cogent Biosciences were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common stock.

In the late-trading session, the stock was down 4.9%, at $9.30. Shares had fallen as low as $8.80 after the bell before recovering some lost ground. The stock finished the day's regular session with a 4.6% gain, closing at $9.78.

The company said proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to its lead drug candidate, bezuclastinib, which is being developed to inhibit cell mutations found in certain cancer patients. Proceeds will also go toward developing other product candidates, including novel targeted therapies to help patients fighting serious, genetically driven diseases, the company said.

All shares in the public offering are being provided by Cogent.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

July 08, 2025 17:03 ET (21:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550573016"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550573016\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550573016?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 05:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550573016","market":"other","top_or_hot":-1,"title":"Cogent Biosciences Shares Fall After Public Offering News","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common stock. \n</p>\n<p>\n  In the late-trading session, the stock was down 4.9%, at $9.30. Shares had fallen as low as $8.80 after the bell before recovering some lost ground. The stock finished the day's regular session with a 4.6% gain, closing at $9.78. \n</p>\n<p>\n  The company said proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to its lead drug candidate, bezuclastinib, which is being developed to inhibit cell mutations found in certain cancer patients. Proceeds will also go toward developing other  product candidates, including novel targeted therapies to help patients fighting serious, genetically driven diseases, the company said. \n</p>\n<p>\n  All shares in the public offering are being provided by <a href=\"https://laohu8.com/S/CCOI\">Cogent</a>. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2025 17:03 ET (21:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cogent Biosciences Shares Fall After Public Offering News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCogent Biosciences Shares Fall After Public Offering News\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-09 05:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common stock. \n</p>\n<p>\n  In the late-trading session, the stock was down 4.9%, at $9.30. Shares had fallen as low as $8.80 after the bell before recovering some lost ground. The stock finished the day's regular session with a 4.6% gain, closing at $9.78. \n</p>\n<p>\n  The company said proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to its lead drug candidate, bezuclastinib, which is being developed to inhibit cell mutations found in certain cancer patients. Proceeds will also go toward developing other  product candidates, including novel targeted therapies to help patients fighting serious, genetically driven diseases, the company said. \n</p>\n<p>\n  All shares in the public offering are being provided by <a href=\"https://laohu8.com/S/CCOI\">Cogent</a>. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2025 17:03 ET (21:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CCOI","symbol_name":"Cogent Communications Group","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550573016","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550573016","pubTimestamp":1752008580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cogent Biosciences were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common stock.In the late-trading session, the stock was down 4.9%, at $9.30. Shares had fallen as low as $8.80 after the bell before recovering some lost ground. The stock finished the day's regular session with a 4.6% gain, closing at $9.78.The company said proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to its lead drug candidate, bezuclastinib, which is being developed to inhibit cell mutations found in certain cancer patients. Proceeds will also go toward developing other  product candidates, including novel targeted therapies to help patients fighting serious, genetically driven diseases, the company said.All shares in the public offering are being provided by Cogent.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CCOI":"Cogent Communications Group","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","BK4505":"高瓴资本持仓","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","COGT":"Cogent Biosciences, Inc.","BK4089":"非传统电信运营商"},"translate_title":"公开发行消息传出后，Cogent Biosciences股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CCOI":1,"COGT":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Shares of Cogent Biosciences were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common stock. \n\n\n  In the late-trading session, the stock was down 4.9%, at $9.30. Shares had fallen as low as $8.80 after the bell before recovering some lost ground. The stock finished the day's regular session with a 4.6% gain, closing at $9.78. \n\n\n  The company said proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to its lead drug candidate, bezuclastinib, which is being developed to inhibit cell mutations found in certain cancer patients. Proceeds will also go toward developing other  product candidates, including novel targeted therapies to help patients fighting serious, genetically driven diseases, the company said. \n\n\n  All shares in the public offering are being provided by Cogent. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2025 17:03 ET (21:03 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}